FDA Gives Complete Response to J&J’s Simponi sBLA
Johnson and Johnson (J&J) subsidiary Janssen Biotech has received a complete response letter for its Simponi sBLA, intended to expand the inflammatory disease drug’s label to include inhibiting the progression and maintenance of reduction of signs and symptoms of rheumatoid arthritis (RA).
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.